184 related articles for article (PubMed ID: 33298767)
1. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Marks EI; Matera R; Olszewski AJ; Yakirevich E; El-Deiry WS; Safran H; Carneiro BA
Am J Clin Oncol; 2021 Feb; 44(2):68-73. PubMed ID: 33298767
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR
J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391
[TBL] [Abstract][Full Text] [Related]
3. First-line Palliative Chemotherapy for Colorectal Cancer: a Population-based Analysis of Delivery and Outcomes in a Single-payer Health System.
Wilson BE; Booth CM; Patel S; Berry S; Kong W; Merchant SJ
Clin Oncol (R Coll Radiol); 2024 Apr; 36(4):211-220. PubMed ID: 38199907
[TBL] [Abstract][Full Text] [Related]
4. Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis.
Hsu CW; King TM; Lin CH; Wang HT; Ou WC; Wang JH
Int J Colorectal Dis; 2009 Apr; 24(4):377-83. PubMed ID: 19116722
[TBL] [Abstract][Full Text] [Related]
5. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
Díaz-Rubio E; Pietrantonio F; de Braud F
Oncologist; 2012; 17(11):1426-8. PubMed ID: 23073991
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Choi IS; Choi M; Lee JH; Kim JH; Suh KJ; Lee JY; Kang B; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(6):e0198544. PubMed ID: 29879177
[TBL] [Abstract][Full Text] [Related]
7. Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.
Boostrom SY; Nagorney DM; Donohue JH; Harmsen S; Thomsen K; Que F; Kendrick M; Reid-Lombardo KM
J Gastrointest Surg; 2009 Nov; 13(11):2003-9; discussion 2009-10. PubMed ID: 19760306
[TBL] [Abstract][Full Text] [Related]
8. Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy.
Okada S; Yamazaki S; Kaiga T; Funada T; Kochi M; Takayama T
World J Surg Oncol; 2017 Aug; 15(1):162. PubMed ID: 28836976
[TBL] [Abstract][Full Text] [Related]
9. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
[TBL] [Abstract][Full Text] [Related]
10. Comparative Analysis of First-Line FOLFOX Treatment With and Without Anti-VEGF Therapy in Metastatic Colorectal Carcinoma: A Real-World Data Study.
Brenner R; Amar-Farkash S; Klein-Brill A; Rosenberg-Katz K; Aran D
Cancer Control; 2023; 30():10732748231202470. PubMed ID: 37724508
[TBL] [Abstract][Full Text] [Related]
11. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.
Sundar R; Miranda S; Rodrigues DN; Chénard-Poirier M; Dolling D; Clarke M; Figueiredo I; Bertan C; Yuan W; Ferreira A; Chistova R; Boysen G; Perez DR; Tunariu N; Mateo J; Wotherspoon A; Chau I; Cunningham D; Valeri N; Carreira S; de Bono J
Clin Colorectal Cancer; 2018 Dec; 17(4):280-284. PubMed ID: 30042009
[TBL] [Abstract][Full Text] [Related]
12. Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer.
McGarrah P; Hubbard J; Novotny PJ; Branda ME; Sargent DS; Morton RF; Fuchs CS; Benson AB; Williamson SK; Findlay BP; Alberts SR; Goldberg RM; Sloan JA
Cancer Control; 2023; 30():10732748231185047. PubMed ID: 37339926
[TBL] [Abstract][Full Text] [Related]
13. A liquid biopsy signature of circulating extracellular vesicles-derived RNAs predicts response to first line chemotherapy in patients with metastatic colorectal cancer.
Yang Y; Zhang J; Zhang W; Wang Y; Zhai Y; Li Y; Li W; Chang J; Zhao X; Huang M; Geng Q; Yang Y; Gong Z; Yu N; Shen W; Li Q; Huang S; Guo W
Mol Cancer; 2023 Dec; 22(1):199. PubMed ID: 38062470
[TBL] [Abstract][Full Text] [Related]
14. Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.
Kagawa Y; Wang C; Piao Y; Jin L; Tanizawa Y; Cai Z; Sunakawa Y
Target Oncol; 2024 May; ():. PubMed ID: 38691296
[TBL] [Abstract][Full Text] [Related]
15. Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
Nasioudis D; Latif NA; Ko EM; Cory L; Kim SH; Martin L; Simpkins F; Giuntoli R
Gynecol Oncol; 2023 Oct; 177():14-19. PubMed ID: 37611378
[TBL] [Abstract][Full Text] [Related]
16. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Nakatani A; Nagayasu K; Sakuyama N; Sato T; Kishine K; Abe Y; Nagaoka I
Oncol Lett; 2019 Feb; 17(2):1842-1850. PubMed ID: 30675246
[TBL] [Abstract][Full Text] [Related]
17. Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.
Klempner SJ; Bhangoo MS; Luu HY; Kim ST; Chao J; Kim KM; Lee J
J Gastrointest Oncol; 2018 Dec; 9(6):1198-1206. PubMed ID: 30603142
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic variants in human DNA damage repair genes mostly arose in recent human history.
Zhao B; Li J; Sinha S; Qin Z; Kou SH; Xiao F; Lei H; Chen T; Cao W; Ding X; Wang SM
BMC Cancer; 2024 Apr; 24(1):415. PubMed ID: 38575974
[TBL] [Abstract][Full Text] [Related]
19. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Boscolo Bielo L; Repetto M; Crimini E; Belli C; Setola E; Parma G; Fusco N; Barberis M; Guerini Rocco E; Marra A; Colombo N; Curigliano G
Oncologist; 2024 May; ():. PubMed ID: 38716772
[TBL] [Abstract][Full Text] [Related]
20. Systemic chemotherapy for unresectable or recurrent primary thymic adenocarcinoma of enteric type.
Gao X
Int Cancer Conf J; 2023 Jan; 12(1):46-48. PubMed ID: 36605837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
